Scott G. Soltys, MD

Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery

Clinical Focus

Cancer > Radiation Oncology
Radiosurgery
Brain Tumors
Spinal Tumors
Trigeminal Neuralgia
Radiation Oncology

Academic Appointments

Professor - University Medical Line, Radiation Oncology - Radiation Therapy
Professor - University Medical Line (By courtesy), Neurosurgery
Member, Stanford Cancer Institute

Honors & Awards

Association of Residents in Radiation Oncology (ARRO) Educator of the Year, Association of Residents in Radiation Oncology (ARRO) (2019)
Sarah S. Donaldson Mentorship Reward, Stanford Radiation Oncology (2017)
Henry Kaplan Memorial Prize for Teaching, Stanford Radiation Oncology (2015)
Young Investigator Award, International Stereotactic Radiosurgery Society (ISRS) (2009)
Henry Kaplan Memorial Prize for Teaching, Stanford Radiation Oncology (2007)
AACR/ASCO Methods in Clinical Cancer Research Workshop Grant, AACR/ASCO (2006)
Malcolm A. Bagshaw Award, Stanford Radiation Oncology (2004)
Oncology Fellows Travel Grant, Annenberg Center for Health Sciences (2003)
RSNA Roentgen Resident Research Award, Radiological Society of North America (2003)
Alpha Omega Alpha, National Medical Honor Society (1999)
Bronze Tablet University Honors, University of Illinois (1995)
Phi Beta Kappa, National Honor Society (1995)

Professional Education

Residency: Stanford University Dept of Radiation Oncology (2005) CA
Board Certification: American Board of Radiology, Radiation Oncology (2006)
Internship: Oakwood Healthcare System (2001) MI
Medical Education: University of Michigan School of Medicine (2000) MI
B.S., University of Illinois, Cell and Structural Biology (1995)
M.D., Univeristy of Michigan, Medicine (2000)

Contact

Academic Tel: (650) 723-8843

Alternate Contact Taryn Kaneko Assistant Clinical Research Coordinator tlka02@stanford.edu Tel: 650-723-8843

Clinical (Primary)

This is the primary clinic for this clinical provider. For additional clinical locations and information, please visit the link(s) listed below in the 'Additional Clinical Info' section.

Department of Radiation Oncology 875 Blake Wilbur Dr Stanford CA 94305 Tel: (650) 736-0845 Fax: (650) 725-8231

Additional Clinical Info

Current Research and Scholarly Interests

My clinical and research interests focus on the development of new radiation techniques involving stereotactic radiosurgery and radiotherapy for the treatment of malignant and benign tumors of the brain and spine, as well as functional disorders such as trigeminal neuralgia.

Clinical Trials

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies Not Recruiting
More
This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
View full details
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases Recruiting
More
This phase III trial compares the addition of stereotactic radiosurgery before or after surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Surgery and radiation may stop the tumor from growing for a few months or longer and may reduce symptoms of brain metastases.
Lead Sponsor
Stanford Investigators
- Scott G. Soltys, MD
- Melanie Hayden Gephart
View full details
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma Not Recruiting
More
The purpose of this study is to determine the safety and efficacy of the combination therapy of TTFields + SRS+ Temozolomide (TMZ) for newly diagnosed glioblastoma (GBM).

Stanford is currently not accepting patients for this trial. For more information, please contact Aniket Pratapneni, 650-723-3110.

Lead Sponsor
- Stanford University
Stanford Investigators
- Chirag Patel, MD, PhD
- Scott G. Soltys, MD
View full details
Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases Not Recruiting
More
The maximum tolerated dose of 3-session (ie, treatment) stereotactic radiosurgery (SRS) to treat brain metastases greater than 4.2 cm³ in size will be determined. This study investigates if increasing radiation dose improves outcome for patients without greater toxicity (side effects).

Stanford is currently not accepting patients for this trial. For more information, please contact Polly Young, 650-497-7499.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Diffusion Tensor Imaging Magnetic Resonance Imaging (DTI MRI) as a Correlate to Pain Relief and Facial Numbness in Patients Following Stereotactic Radiosurgical Rhizotomy for Trigeminal Neuralgia Not Recruiting
More
Trigeminal neuralgia or tic douloureux is severe, often debilitating, facial pain that significantly impairs the patient's quality of life and health. Stereotactic radiosurgery has been shown to provide pain relief in majority of patients treated. However, a common side effect of radiosurgery is facial numbness. To better understand how radiosurgery can bring about pain relief and facial numbness, we are conducting a study in which brain MRI scans will be done following stereotactic radiosurgery to learn if there are any changes in the MRI scans that correlate with symptoms.

Stanford is currently not accepting patients for this trial. For more information, please contact Lisa Jacobs, 650-723-8843.

Lead Sponsor
- Stanford University
Stanford Investigators
- Scott G. Soltys, MD
View full details
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer Not Recruiting
More
The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain metastases in patient with 1-4 lesions.

Stanford is currently not accepting patients for this trial. For more information, please contact Maria Coburn, 6507369551.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform Not Recruiting
More
The purpose of this study is to investigate the safety and effectiveness of a combination treatment for glioblastoma multiforme utilizing radiotherapy plus the FDA-approved chemotherapy drug temozolomide

Stanford is currently not accepting patients for this trial. For more information, please contact Polly Young, 650-497-7499.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis Not Recruiting
More
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This randomized phase II/III trial is studying how well image-guided radiosurgery or stereotactic body radiation therapy works and compares it to external-beam radiation therapy in treating patients with localized spine metastasis.

Stanford is currently not accepting patients for this trial. For more information, please contact Alifia Hasan, 650-725-1723.
Lead Sponsor
Stanford Investigators
View full details
A Study of Amifostine for Prevention of Facial Numbness in Radiosurgery Treatment of Trigeminal Neuralgia Not Recruiting
More
Trigeminal neuralgia or tic douloureux is severe, often debilitating, facial pain that significantly impairs the patient's quality of life and health. Stereotactic radiosurgery has been shown to provide pain relief in majority of patients treated. However, a common side effect of radiosurgery is facial numbness. Our goal is to maximize pain control while minimizing side effects. To this end, the purpose of this study is to evaluate whether adding a drug, amifostine, at the time of radiosurgery will protect patients from facial numbness.

Stanford is currently not accepting patients for this trial. For more information, please contact Lisa Jacobs, 650-723-8843.

Lead Sponsor
- Stanford University
Stanford Investigators
- Scott G. Soltys, MD
View full details
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors Not Recruiting
More
RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy. PURPOSE: This randomized phase III trial is studying memantine to see how well it works compared to a placebo in preventing side effects caused by whole-brain radiation therapy in patients with brain metastases from solid tumors.

Stanford is currently not accepting patients for this trial. For more information, please contact Leslie Modlin, 6507238843.
Lead Sponsor
Stanford Investigators
View full details
Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer Not Recruiting
More
Treatment of rectal cancer often consists of surgical resection of the tumor. Chemotherapy and/or radiotherapy are frequently given before or after surgery. In this study, we wish to learn if there are differences in the treatment effectiveness or in the quality of life of patients based on their type of treatment (e.g. Radiotherapy and chemotherapy before or after surgery). Information from this questionnaire collected from you and other patients may help improve the quality of life of rectal cancer patients in the future. Medical information on your tumor, treatment received, and side effects will be compiled and maintained in a database to learn more about outcomes of treatment for rectal cancer.

Stanford is currently not accepting patients for this trial. For more information, please contact Moe Jalali, 6507244023.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases Not Recruiting
More
This randomized phase III trial compares memantine hydrochloride and whole-brain radiotherapy with or without hippocampal avoidance in reducing neurocognitive decline in patients with cancer that has spread from the primary site (place where it started) to the brain. Whole brain radiotherapy (WBRT) is the most common treatment for brain metastasis. Unfortunately, the majority of patients with brain metastases experience cognitive (such as learning and memory) deterioration after WBRT. Memantine hydrochloride may enhance cognitive function by binding to and inhibiting channels of receptors located in the central nervous system. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Using radiation techniques, such as intensity modulated radiotherapy to avoid the hippocampal region during WBRT, may reduce the radiation dose to the hippocampus and help limit the radiation-induced cognitive decline. It is not yet known whether giving memantine hydrochloride and WBRT with or without hippocampal avoidance works better in reducing neurocognitive decline in patients with brain metastases.

Stanford is currently not accepting patients for this trial. For more information, please contact Polly Young, 650-497-7499.
Lead Sponsor
Stanford Investigators
View full details
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery Not Recruiting
More
This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Scott G. Soltys, MD
View full details
A Study of Patient Reported Outcomes After Stereotactic Radiosurgical Rhizotomy for Trigeminal Neuralgia Not Recruiting
More
The investigators know little about how patients feel following radiosurgery treatment of trigeminal neuralgia. Patient satisfaction may ultimately be one of the most important outcome measures for an individual patient; however, this has not been adequately assessed or followed. Multiple questions remain unanswered, including whether there is a correlation between patient satisfaction, the level of their current pain score, and the presence and degree of facial numbness, a possible side effect after radiosurgery. Therefore, the goal of this study is to gather this information from the patients who received radiosurgery for trigeminal neuralgia at Stanford and evaluate post-treatment patient satisfaction, the degree of facial numbness, and current pain score. This data will help the investigators understand outcomes that are important for patient satisfaction following treatment of a chronic pain syndrome.

Stanford is currently not accepting patients for this trial. For more information, please contact Lisa Jacobs, 650-723-8843.

Lead Sponsor
- Stanford University
Stanford Investigators
- Scott G. Soltys, MD
View full details
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Not Recruiting
More
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. PURPOSE: This phase II trial is studying how well avoiding the hippocampus during whole-brain radiation therapy works in treating patients with brain metastases.

Stanford is currently not accepting patients for this trial. For more information, please contact Jacob Wynne, 6507238843.
Lead Sponsor
Stanford Investigators
View full details

2024-25 Courses

Independent Studies
- Directed Reading in Radiation Oncology
  RADO 299 (Aut, Win, Spr, Sum)
- Early Clinical Experience in Radiation Oncology
  RADO 280 (Aut, Win, Spr, Sum)
- Graduate Research
  RADO 399 (Aut, Win, Spr, Sum)
- Medical Scholars Research
  RADO 370 (Aut, Win, Spr, Sum)
- Readings in Radiation Biology
  RADO 101 (Aut, Win, Spr, Sum)
- Undergraduate Research
  RADO 199 (Aut, Win, Spr, Sum)

Find a doctor

Clinics & Services

Research Resources

Professional Training

Education Resources

Scott G. Soltys, MD

Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery

Stanford Investigators

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Stanford Investigators

Lead Sponsor

Stanford Investigators

Stanford Investigators

Lead Sponsor

Stanford Investigators

Stanford Investigators

Stanford Investigators

Lead Sponsor

Stanford Investigators

Stanford Investigators

2024-25 Courses